BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
- 1 May 2016
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 101, 32-39
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Alternative dosing of dual PI3K and MEK inhibition in cancer therapyBMC Cancer, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- The Prevalence and Prognostic Value of BRAF Mutation in Thyroid CancerAnnals of Surgery, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Mutations of the BRAF gene in human cancerNature, 2002